181
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Pharmacokinetic Evaluation by Modeling and Simulation Analysis of a Donepezil Patch Formulation in Healthy Male Volunteers

, ORCID Icon, , , & ORCID Icon
Pages 1729-1737 | Published online: 05 May 2020

References

  • SmallGW, RabinsPV, BarryPP, et al. Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer’s Association, and the American Geriatrics Society. JAMA. 1997;278(16):1363–1371. doi:10.1001/jama.1997.035501600830439343469
  • JingshuX, StefanoP, NitinR, et al. Regional protein expression in human Alzheimer’s brain correlates with disease severity. Commun Biol. 2019;2:34. doi:10.1038/s42003-018-0254-930701199
  • SeeleyWW, MillerBL. Harrison’s Principles of Internal Medicine. 2015.
  • KonstantinaGY, SokratisGP. Current and future treatments for Alzheimer’s disease. Ther Adv Neurol Disord. 2013;6(1):19–33. doi:10.1177/175628561246167923277790
  • BrookmeyerR, GrayS, KawasC. Projections of Alzheimer’s disease in the United States and the public health impact of delaying disease onset. Am J Public Health. 1998;88(9):1337–1342. doi:10.2105/ajph.88.9.13379736873
  • FrancisPT, PalmerAM, SnapeM, WilcockGK. The cholinergic hypothesis of Alzheimer’s disease: a review of progress. J Neurol Neurosurg Psychiatry. 1999;66(2):137–147. doi:10.1136/jnnp.66.2.13710071091
  • DooleyM, LambHM. Donepezil: a review of its use in Alzheimer’s disease. Drugs Aging. 2000;16(3):199–226. doi:10.2165/00002512-200016030-0000510803860
  • StephenJ, RichardJH, DavidW. The safety and tolerability of donepezil in patients with Alzheimer’s disease. Br J Clin Pharmacol. 2004;58(s1):1–8. doi:10.1111/j.1365-2125.2004.01848.x
  • BurnsA, RossorM, HeckerJ, et al. The effects of donepezil in Alzheimer’s disease – results from a multinational trial. Dement Geriatr Cogn Disord. 1999;10(3):237–244. doi:10.1111/j.1365-2125.2004.01848.x10325453
  • RogersSL, FarlowMR, DoodyRS, MohsR, FriedhoffLT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology. 1998;50(1):136–145. doi:10.1212/wnl.50.1.1369443470
  • WinbladB, CummingsJ, AndreasenN, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer’s disease – rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22(5):456–467. doi:10.1002/gps.178817380489
  • MercierF, LefévreG, HuangHL, SchmidliH, AmzalB, Appel-DingemanseS. Rivastigmine exposure provided by a transdermal patch versus capsules. Curr Med Res Opin. 2007;23(12):3199–3204. doi:10.1185/030079908X25343818001519
  • KimYH, ChoiHY, LimH-S, et al. Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers. Drug Des Devel Ther. 2015;9:1419–1426. doi:10.2147/DDDT.S78555
  • BenetLZ, Zia-AmirhosseiniP. Basic principles of pharmacokinetics. Toxicol Pathol. 1995;23(2):115–123. doi:10.1177/0192623395023002037569664